TNFRSF8 positive

P=N/A, N=1000, Completed, Takeda | Active, not recruiting --> Completed

Although uncommon, primary cardiac lymphoma should be considered in patients with unexplained SVC syndrome, particularly when anticoagulation fails or imaging demonstrates right atrial involvement. Early tissue diagnosis is essential, as prompt initiation of chemotherapy may improve outcomes in this aggressive yet potentially treatable malignancy.

TUGSE in children manifests as refractory recurrences, requiring histopathological diagnosis to exclude malignancies and other diseases. Local treatment can alleviate symptoms, but long-term recurrences suggest the need for further exploration of underlying etiologies and personalized interventions.

Despite advances such as brentuximab vedotin-based regimens in CD30-positive disease, relapse rates remain high, particularly in relapsed/refractory (R/R) PTCL...Novel targeted agents, epigenetic therapies, bispecific antibodies, and emerging cellular approaches are reshaping the therapeutic landscape and may serve as effective bridges to allo-HCT or as post-transplant maintenance strategies. This review summarizes current evidence regarding the role of allo-HCT in PTCL, discusses patient selection and transplant-related variables, and explores evolving strategies aimed at improving survival while minimizing toxicity.

P2, N=23, Recruiting, University of California, Davis | Trial completion date: Dec 2026 --> May 2028 | Trial primary completion date: Dec 2026 --> Dec 2027

The patient was treated with brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone, following which the febrile episodes improved. This case illustrates an uncommon gastrointestinal-predominant presentation of ALK-negative systemic ALCL presenting as fever of unknown origin. This case underscores the importance of continued diagnostic reassessment and symptom-guided tissue acquisition when conventional staging studies are not initially diagnostic, particularly in patients with a history of indolent lymphoma.

After nivolumab discontinuation and transition to avelumab, the patient experienced complete metabolic resolution of cardiac involvement, improvement in cardiac biomarkers, and durable control of cutaneous lymphoma over more than 3 years of follow-up. This case highlights a temporal association between programmed cell death-1 blockade and atypical dissemination of cutaneous T-cell lymphoma, supported by biologic plausibility, and underscores a potential therapeutic distinction between programmed cell death-1 and programmed death ligand-1 inhibition in malignant T-cell disorders.

P1, N=10, Suspended, University of Alabama at Birmingham | Trial completion date: Jul 2026 --> Jul 2027 | Recruiting --> Suspended | Trial primary completion date: Apr 2026 --> Jun 2027

BV is a key therapy for CD30-positive CTCL. While real-world experience suggests potential activity in CD30-negative or low disease, prospective trials are needed to define its role in this challenging subgroup.

Current evidence suggests a possible oncogenic interaction between hereditary susceptibility and chronic implant-associated inflammation. Clinicians must maintain vigilance for BIA-ALCL even in prophylactic settings, as early diagnosis and complete surgical excision remain key to favorable outcomes.

P1, N=60, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2026 --> Apr 2027